Historique
Bulletin de Périodique
BMC Infectious Diseases , Vol.14, Suppl.6 - 19 September 2014 - Viral hepatitis and drug use in Europe
Auteur(s) :
LAZARUS, J. V. (Éditeur scientifique) ;
FENTON, K. A. (Éditeur scientifique)
Paru le :
19/09/2014
Année :
2014
Sous-type de document :
N° spécial de revue / Special issue of a journal
Langue(s) :
Anglais
Domaine :
Drogues illicites / Illicit drugs
Discipline :
MAL (Maladies infectieuses / Infectious diseases)
Note de contenu :
CONTENTS:
- Hepatitis - a devastating epidemic in Europe. Lazarus J.V., Fenton K.A., S1.
- No strategy to meet the HCV epidemic. Dalgard O., Mauss S., S2.
- Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe. Kautz A., Chavdarova L., Walker M., S3.
- Ending the mass criminalisation of people who use drugs: a necessary component of the public health response to hepatitis C. Ford C., Bressan J., S4.
- A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. Phelan M., Cook C., S5.
- A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia. Maticic M., S6.
- The successful implementation of Scotland's Hepatitis C Action Plan: what can other European stakeholders learn from the experience? A Scottish voluntary sector perspective. Wylie L., Hutchinson S., Liddell D., Rowan N., S7.
- Improving the quality of needle and syringe programmes: an overlooked strategy for preventing hepatitis C among people who inject drugs. Leicht A., S8.
- Consensus for the integrated management of hepatitis C in Portugal. Leite R., S9.
- A perspective from drug user organisations on 'ECDC and EMCDDA guidance: prevention and control of infectious diseases among people who inject drugs'. Corbacho A., Rivera M., Trujillo F., Marti M., Carbonell J., Fernandez F., et al., S10.
- A policy-maker's perspective on 'ECDC and EMCDDA guidance: prevention and control of infectious diseases among people who inject drugs'. Farran J.C., S11.
- Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities. Heimer R., Eritsyan K., Barbour R., Levina O.S., S12.
- HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective. Peters L., Mocroft A., Lundgren J., Grint D., Kirk O., Rockstroh J., S13.
- Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries. Maticic M., Videcnik Zorman J., Gregorcic S., Schatz E., Lazarus J.V., S14.
- Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey. Spina A., Eramova I., Lazarus J.V., S15.
- A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region. Lazarus J.V., Sperle I., Maticic M., Wiessing L., S16.
- Hepatitis C in European prisons: a call for an evidence-informed response. Arain A., Robaeys G., Stover H., S17.
- Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis. Lazarus J.V., Lundgren J., Casabona J., Wiessing L., Mathei C., Vickerman P., et al., S18.
- Hepatitis - a devastating epidemic in Europe. Lazarus J.V., Fenton K.A., S1.
- No strategy to meet the HCV epidemic. Dalgard O., Mauss S., S2.
- Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe. Kautz A., Chavdarova L., Walker M., S3.
- Ending the mass criminalisation of people who use drugs: a necessary component of the public health response to hepatitis C. Ford C., Bressan J., S4.
- A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. Phelan M., Cook C., S5.
- A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia. Maticic M., S6.
- The successful implementation of Scotland's Hepatitis C Action Plan: what can other European stakeholders learn from the experience? A Scottish voluntary sector perspective. Wylie L., Hutchinson S., Liddell D., Rowan N., S7.
- Improving the quality of needle and syringe programmes: an overlooked strategy for preventing hepatitis C among people who inject drugs. Leicht A., S8.
- Consensus for the integrated management of hepatitis C in Portugal. Leite R., S9.
- A perspective from drug user organisations on 'ECDC and EMCDDA guidance: prevention and control of infectious diseases among people who inject drugs'. Corbacho A., Rivera M., Trujillo F., Marti M., Carbonell J., Fernandez F., et al., S10.
- A policy-maker's perspective on 'ECDC and EMCDDA guidance: prevention and control of infectious diseases among people who inject drugs'. Farran J.C., S11.
- Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities. Heimer R., Eritsyan K., Barbour R., Levina O.S., S12.
- HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective. Peters L., Mocroft A., Lundgren J., Grint D., Kirk O., Rockstroh J., S13.
- Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries. Maticic M., Videcnik Zorman J., Gregorcic S., Schatz E., Lazarus J.V., S14.
- Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey. Spina A., Eramova I., Lazarus J.V., S15.
- A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region. Lazarus J.V., Sperle I., Maticic M., Wiessing L., S16.
- Hepatitis C in European prisons: a call for an evidence-informed response. Arain A., Robaeys G., Stover H., S17.
- Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis. Lazarus J.V., Lundgren J., Casabona J., Wiessing L., Mathei C., Vickerman P., et al., S18.